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OBJECTIVES: In the secondary prevention of cardio-
vascular disease patient compliance with established 
risk-reducing factors remains inadequate. The primary
objective of the ORBITAL Study is to evaluate the impact
of a compliance enhancing program in patients receiving
statin therapy on long-term disease-related outcomes and
costs. Here the design and results of the pilot phases are
presented. METHODS: Approximately 7000 patients 
eligible for statin therapy (Joint European Guidelines) will
be enrolled nationwide in primary care practices in
Germany. Patients will be randomised into an interven-
tion group (12-month rosuvastatin plus compliance
program) and a control group (12-month rosuvastatin
alone). Disease-related costs, quality of life, cardiovascu-
lar events, and compliance will be assessed every 6
months during the 36 months follow-up. The compliance
program was developed based on previous studies, expert
advice, and pilot testing, and includes a start package
with a video and an information brochure, followed by
mailings and telephone calls. The program addresses
factors such as diet and lifestyle in addition to compli-
ance with pharmacotherapy. The information brochure
and telephone calls were evaluated in two subsequent
pilot phases. RESULTS: In the ﬁrst pilot phase, 23 of 25
contacted patients in a cardiac rehabilitation center con-
sidered the brochure to be easy to understand although
some criticized the use of too many medical terms. 17%
of patients considered the brochure to be too long. In 
the second pilot phase, 70 patients were randomised 
into intervention (n = 37) or control (n = 33) groups. The
majority of the intervention patients expressed high sat-
isfaction with the telephone calls although 10% indicated
the calls contained too much information and should be
shortened. CONCLUSION: With regard to the compli-
ance initiatives evaluated, the importance of not over-
loading patients with information became apparent.
Therefore, the compliance enhancing program was
revised accordingly for the main phase of the ORBITAL
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The chronic heart failure (CHF) is a chronic illness typi-
cally characterized by phases of clinical deterioration
requiring hospitalitation. The relief continuity is a fun-
damental element to better the effectiveness of the sani-
tary intervention. The Day-Hospital (DH), particularly,
could represent a valid tool to guarantee the relief conti-
nuity and to extend the phases of clinical stability in
patients with CHF. OBJECTIVES: The aim of this study
was to compare the managerial effectiveness and
Cost/Utility ratio between heart failure management
program delivered by day-hospital and usual care.
METHODS: Two hundred thirty-four consecutive
patients (M/F: 196/38; 56 ± 10 years) with chronic heart
failure (EF 29 ± 7%) referred to UHF were evaluated.
After clinical evaluation and therapuetic optimization,
122 patients received usual care (UC) and follow-up
(control every 6 months), despite 112 patients were acti-
vated in the DH. The DH program foresaw: 1) risk proﬁle
identiﬁcation; 2) objectives deﬁnition; 3) sanitary run
determination; 4) outcome markers measurement; and 5)
territory interaction (physician of family and/ or cardiol-
ogist of reference). Management (optimezed therapy and
Hospital readmission for heart failure (HRHF), func-
tional (NYHA functional class, Left ventricular ejection
fraction (LVEF)) and hard (cardiac death and urgent heart
transplantation) outcomes during 258 ± 88 days of
follow-up were considered. Cost/utility ratio of two
strategies were calculated. RESULTS: At baseline not
clinical and functional differences between two groups
were found. Hard cardiac events occured in 21/122
(17.2% on usual care (UC) and in 4/112 (3.6%) in DH
patients (p < .0007). The cost/utility ratio of two strate-
gies was similar (UC 2409$ vs DH $2244). The incre-
mental analysis pointed out for each gained Qaly in DH
a cost-saving of $1068. The cost-utility ratio for integra-
tion of Day Hospital to manage chronic heart failure was
$19,462(13,904–34,048). CONCLUSIONS: heart failure
management program delivered by day-hospital can
reduce mortality and morbidity of CHF patients. This
management strategy is cost-effective and has an equi-
table cost from a society point of view.
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OBJECTIVE: To study the incidence and cost of man-
agement of deep vein thrombosis (DVT), and to estimate
the cost avoidance due to prophylactic therapy in a group
of Hong Kong Chinese patients undergoing total hip
replacement (THR). METHOD: All Chinese patients
undergoing THR from November 98 to December 2001
at the Prince of Wales Hospital in Hong Kong were ret-
rospectively evaluated. In those patients who developed
DVT, the cost of management was estimated by identify-
ing the total healthcare resources used. The cost avoid-
ance of DVT by using prophylactic low-molecular-weight
heparin LMWH (nandroparin calcium) was estimated by
construction of a decision tree model. Sensitivity analysis
was performed to examine whether the results were
robust to changes in the key variables. The study was per-
formed from the perspective of a publicly funded hospi-
tal. RESULTS: A total of 90 Chinese patients underwent
THR surgery over the study period and their baseline
characteristics were comparable. Six had symptomatic
DVT, yet only three were conﬁrmed by Doppler ultra-
sonography. The incidence of symptomatic DVT in this
group of Hong Kong Chinese was therefore 3.33%. 
The treatment costs after THR surgery with or without
DVT per patient were HKD129,980 (119,740–
140,210) (median (25%,75%)) (1USD = 7.8HKD) and
HKD79,410 (73,860–84,960) respectively. The cost of
management of DVT without prophylaxis was
HKD53,570 (39,980–67,170) per patient. A close to
70% reduction in cost was possible if LMWH prophy-
laxis was used. CONCLUSION: The incidence of symp-
tomatic DVT in the present group of Hong Kong Chinese
patients after THR surgery was similar to that in the 
Caucasians. According to the decision-tree model, cost
avoidance appears to be possible by using LMWH for
prophylaxis of DVT in high-risk orthopaedic procedures.
Prophylactic antithrombotic therapy should be consid-
ered for routine use in THR surgery.
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OBJECTIVE: Cost-effectiveness analysis of treatments 
to reduce cholesterol concentration, blood pressure and
smoking for the primary prevention of coronary heart
disease in Catalonia (Spain) was assessed in this study.
METHODS: Cost-effectiveness was measured in terms of
met cost per life year gained (LYG), comparing costs and
beneﬁts from coronary heart disease in individuals aged
>30 years with hypercholesterolemia >200mg/dl, moder-
ate/severe (DBP > 105mmHg) and mild (DBP 95–104
mmHg) hypertension and smoking. Cost-effectiveness
ratios were calculated for 1998 using a 5% discount rate.
RESULTS: Cost-effectiveness ratios obtained in this study
ranged from €2,608 to €8,058 per LYG for smoking ces-
sation therapies, from €7,061 to €81,027 per LYG for
moderate/severe hypertension treatment, from €10,877 to
€126,990 per LYG for mild hypertension treatment, and
from €12,792 to €142,910 per LYG for dietary and phar-
maceutical treatment of hypercholesterolemia. Incremen-
tal cost-effectiveness analysis showed that lovastatin
(HMG-CoA reductase inhibitor) was more cost-effective
than cholestyramine (bile acid sequestrant) and gemﬁ-
brozil (ﬁbrate) in individuals with hypercholesterolemia,
hydrochlorothiazide (diuretic) and propranolol (beta-
adrenergic antagonist) were more cost-effective than 
captopril (angiotensin-converting-enzyme inhibitor), 
prazosin (alpha-adrenergic antagonist) and nifedipine
(calcium channel blocker) in individuals with moder-
ate/severe hypertension treatment, and hydrochloroth-
iazide and nifedipine were more cost-effective than
propranolol, prazosin and captopril in individuals with
mild hypertension treatment. CONCLUSION: When
resources for the primary prevention of coronary heart
disease are limited, the priority order based on cost-
effectiveness analysis was smoking cessation, hyperten-
sion treatment and hypercholesterolemia treatment.
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OBJECTIVES: To evaluate the pharmacoeconomics of
hawthorn-extract treatment of CHF at stage NYHA II, 
a prospective 3-year observational study has been con-
ducted since summer 1999. A cost-utility-analysis (CUA)
will compare hawthorn treatment (WS 1442 as mono- 
or add-on-therapy) to any other treatment option. The
results of two years of study conduct are presented.
METHODS: Open, non-randomized observational
cohort study with matched-pairs evaluation. The ﬁrst
cohort (Hawthorn-Cohort, HC) comprises patients
receiving hawthorn-extract therapy of CHF. In the second
cohort (Conventional-Cohort, CC) patients without
hawthorn but any other treatment were observed. In 217
study centres 952 patients were included (HC: 588; CC:
364). A number of 116 pairs were determined as sample
size necessary for evaluation. For measuring HRQL the
EuroQoL-5D was used. Matching criteria were derived
from demographic factors and clinical diagnosis. The per-
spective of the German statutory health insurance funds
was applied. RESULTS: 130 pairs could be established
under consideration of two-year data. Median direct costs
per year for HC amounted to €473 and for CC to €449.
This difference is not signiﬁcant (p = .218). Most impor-
